Autolomous key facts
as of Oct 2026- Developer of a healthcare manufacturing data management platform intended to support the development and delivery of advanced medicines.
- Autolomous is valued at approximately $29.5M as of Oct 2026 (last reported valuation).
- It has raised $12.8M; the latest was Later Stage VC ($4.4M) in Mar 2025.
- Notable investors include Innovate UK, MedTech Innovator, BioTools Innovator, Aescuvest, CMS equIP — 7 tracked in total.
- Status: Privately Held (backing).
Autolomous's last reported valuation, Sep 2024. Nothing priced has surfaced since.
- ·Watch Autolomous: the Monday email on marks, rounds and moves
Autolomous funding rounds
No funding rounds for Autolomous are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Autolomous valuation
Autolomous's last reported valuation was $29.5 million in Sep 2024. No priced round, secondary trade or fund mark has surfaced since.
Autolomous investors
7 investors are on record for Autolomous, including Innovate UK, MedTech Innovator, BioTools Innovator and Aescuvest.
About Autolomous
Developer of a healthcare manufacturing data management platform intended to support the development and delivery of advanced medicines. The company offers laboratory-friendly software that securely transfers manufacturing data to a cloud-based system with immutable data tracking, scheduling tools, and digital quality approvals, enabling therapy developers to manage manufacturing processes efficiently and improve the accessibility of advanced medicines.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 37
- Website
- autolomous.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.